Content for healthcare professionals only

View all Platforms Cardiology

Topics Content Type Videos Articles Journals Broadcasts Education Podcasts News Journals AER CFR ECR ICR3 JAPSC USC Faculty Events Upcoming Events Radcliffe Events All Events Resource Hubs Empagliflozin in the Treatment of Chronic Heart Failure Pulmonary Embolism Pulsed Field Ablation

Radcliffe Platforms

Radcliffe Group Cardiology Vascular CVRM Medical Education

Content for healthcare professionals only

Content Type

Events

Resource Hubs

Images

Filter by

Topics

Newer than

Figure 2 An Approach To The Management of Patients Presenting With Valve Thrombosis Early After Transcatheter Aortic Valve Implantation

Figure 2: An Approach To The Management of Patients Presenting With Valve Thrombosis Early After Transcatheter Aortic Valve Implantation

Figure 1 Kaplan–Meier curves for key study outcomes of PARADIGM-HF trial according to study group

Figure 1: Kaplan–Meier curves for key study outcomes of PARADIGM-HF trial according to study group

Figure 2 Kaplan–Meier cumulative event curves for death from heart failure A and all-cause death in the Systolic Heart Failure

Figure 2: Kaplan–Meier cumulative event curves for death from heart failure (A) and all-cause death in the Systolic Heart Failure

table 1-summary-of-transcatheter-aortic-valve

Clinical Practice Update: Who Should Be Referred for Transcatheter Aortic Valve Replacement in 2017?

Figure 1 Acute and long-term success rates after ablation of premature ventricular complexes

Figure 1: Acute and long-term success rates after ablation of premature ventricular complexes

Table 1 Ten Key Points Regarding PCSK9 LDL-cholesterol and Cardiovascular Disease

Table 1: Ten Key Points Regarding PCSK9, LDL-cholesterol, and Cardiovascular Disease

Table 1 Overview of Novel Approved Pharmacologic Treatments for Cardiovascular Disease

Table 1: Overview of Novel, Approved Pharmacologic Treatments for Cardiovascular Disease

Figure 1 Anticoagulant Usage at the Time of Event in Patients Experiencing a Thrombotic Event in RE-VERSE AD and ANNEXA-4

Figure 1: Anticoagulant Usage at the Time of Event in Patients Experiencing a Thrombotic Event in RE-VERSE AD and ANNEXA-4

Figure 1 MACE-free Survival in Patients of the Medical Therapy Group Stratified by FFR Strata

Figure 1: MACE-free Survival (%) in Patients of the Medical Therapy Group Stratified by FFR Strata

Figure 2 Results from the DANAMI3–PRIMULTI Study

Figure 2: Results from the DANAMI3–PRIMULTI Study

Figure 3 Results from the DKCRUSH VII Registry Study

Figure 3: Results from the DKCRUSH VII Registry Study

Figure 4 Among Patients with Coronary Artery Disease

Figure 4: Among Patients with Coronary Artery Disease